APP (Amyloid Beta Precursor Protein)

This study is the first to integrate bibliometric and bioinformatics methods, revealing the macro-level trends in OP-ATG research and the molecular mechanisms underlying OP-LP crossover. It successfully identified five key OP-LP targets, providing a new perspective for understanding OP mechanisms and developing targeted therapies.

Deleting the lysosomal lipid hydrolase NAAA in oligodendrocytes prevents both injury-induced Aβ production and chronic pain development. The findings identify an unexpected mechanistic link between chronic pain and Alzheimer's-like neurodegeneration, positioning Aβ as a target for therapeutic intervention.

Moreover, we elucidated the molecular mechanism through which the pre-B-cell leukemia transcription factor 1-insulin receptor substrate 1 signaling axis sustains metabolic homeostasis. Furthermore, we demonstrated that the blood-brain barrier-permeable trans-activator of transcription-pre-B-cell leukemia transcription factor 1 fusion protein constitutes a mechanistically innovative and highly translatable therapeutic strategy for Alzheimer's disease.

Mitogen-Activated Protein Kinases (MAPKs), cytosol, kinase binding, and regulation of apoptotic processes represent the key signaling pathways, cellular components, molecular functions, and biological processes involved. The results of the current study demonstrate that GSK3β and CypA contribute to clarifying the mechanisms underlying AD pathophysiology in cellular studies related to this disorder.

Androgen signaling modulates APP processing in cancer, particularly through the non-amyloidogenic pathway; however, significant knowledge gaps remain. Further studies are needed to explore the interaction between androgens and APP processing in other cancer types, as well as to elucidate downstream signaling pathways regulated at the gene expression level.

LA-TAM plays a key role in immune suppression and metabolic regulation in GC. Its key genes form a high-precision prognosis model, and endothelial cell-expressed APP may promote immune evasion by enhancing macrophage PD-1 expression, suggesting a potential target for immunotherapy.

Here, we highlight reports on non-neuronal Aβ production in the context of AD and the function of APP processing in these cells. Understanding Aβ processing in non-neuronal cells might enable the identification of novel therapeutic targets, especially in humans whose brain structures differ greatly from animal models.

Oleacein, one of the most abundant polyphenols in Extra Vergin Olive Oil (EVOO) may exert neuroprotective and/or antitumor effects. In this study, we explored the effects of the polyphenol oleacein, obtained by a simple and efficient sustainable semi-synthesis starting from natural oleuropein, on AD-related genes in SHSY5Y, a human neuroblastoma cell line, and in 3Tg-iAstro cells, immortalized astrocytes from the hippocampus of 3xTg-AD mice, to identify potential shared biological pathways.

Our finding demonstrates that long-lasting exposure to low levels of DZN in adulthood stimulates APP degradation, possibly contributing to poor cognitive outcomes.

Ang-1 and ApoE exhibited promising predictive potential in prostate cancer progression, whereas NF-κB p65 and PEN-2 demonstrated modest discriminative performance. FOXA2 showed expression variation across disease stages but lacked sufficient diagnostic value. These results highlight the diverse molecular profiles involved in prostate cancer biology and underline the need for validation in larger cohorts before clinical application.

In this study, we characterized the effects of other CTS-marinobufagenin, bufalin, and digoxin, on APP level in these cells...It means that CTS binding to Na,K-ATPase alters its interaction with Aβ42. Taken together, these results show that endogenous CTS are important regulators that can maintain the balance between APP and beta-amyloid in the brain.

These findings advance our understanding of the proteolytic mechanisms of GSEC, which is important for the further development of GSEC inhibitors and modulators in cancer and Alzheimer's disease therapies.